BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Timing is Right for Big Pharma to Add Nuvilex Technology to Its Pipeline


3/21/2013 10:06:01 AM

NEW YORK, NY--(Marketwire - March 21, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has close to $30-million invested in its "Cell-in-a-Box" technology, and as the company gets closer to the start of its Phase III pancreatic cancer trial, the trial may be coming at just the right time!

Over the past month, Stock House Group, an investment relations firm specializing in research, content development and market awareness, has laid out a series of articles that outline how the living cell encapsulation or "Cell-in-a-Box" technology at Nuvilex can dramatically change the treatments we use for many serious, debilitating, and even fatal diseases.

From the company's clinical trials with patients suffering from advanced, inoperable, pancreatic cancer to its work in diabetes studies to create a type of "artificial pancreas" in order to eliminate the need for daily insulin requirements, to its potential to revive the excitement surrounding the use of stem cells and even to its move into the medical marijuana space which will initially focus on pancreatic cancer and cancers of the brain, Nuvilex has invested a lot of capital and time into its technology. This is time and money that has a value and price tag to a larger biotechnology or pharmaceutical company.

The fact that the company has completed two independent cancer trials and is prepping for a late-stage trial, could quite possibly leave Nuvilex sitting at just the right place, at just the right time. Earlier this year at JPMorgan's annual healthcare conference in San Francisco, Bloomberg stated in an article that the days of the big deals in the industry are back. More than 400 companies attended the conference to make their presentations, schedule one-on-one meetings and to get a sense of available and competing assets.

Continue reading the rest of this article at www.stockhousegroup.com/features

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES